{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:23:24Z","timestamp":1774085004675,"version":"3.50.1"},"reference-count":82,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":103,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1111\/ane.12437","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T11:18:54Z","timestamp":1432207134000},"page":"4-16","source":"Crossref","is-referenced-by-count":31,"title":["Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics"],"prefix":"10.1155","volume":"133","author":[{"given":"H. A.","family":"Gefroh-Grimes","sequence":"first","affiliation":[{"name":"Pharmacy Practice Division; School of Pharmacy; University of Wisconsin-Madison; Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. E.","family":"Gidal","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Department of Neurology; University of Wisconsin-Madison; Madison WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"10.1111\/ane.12437-BIB0001|ane12437-cit-0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009","volume":"14","author":"Dolecek","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1111\/ane.12437-BIB0002|ane12437-cit-0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.critrevonc.2013.01.007","article-title":"The treatment of glioblastomas: a systematic update on clinical Phase III trials","volume":"87","author":"Yin","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/ane.12437-BIB0003|ane12437-cit-0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PPO.0b013e318244d7eb","article-title":"Status quo-standard-of-care medical and radiation therapy for glioblastoma","volume":"18","author":"Becker","year":"2012","journal-title":"Cancer J"},{"key":"10.1111\/ane.12437-BIB0004|ane12437-cit-0004","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.mehy.2012.07.037","article-title":"Gliomas and seizures","volume":"79","author":"Prakash","year":"2012","journal-title":"Med Hypotheses"},{"key":"10.1111\/ane.12437-BIB0005|ane12437-cit-0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/epi.12452","article-title":"Optimizing antiepileptic drug treatment in tumoral epilepsy","volume":"54S9","author":"Perucca","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12437-BIB0006|ane12437-cit-0006","unstructured":"Dutch Society for Neuro-Oncology Gliomas"},{"key":"10.1111\/ane.12437-BIB0007|ane12437-cit-0007","first-page":"CD008586","article-title":"Antiepileptic drugs for treating seizures in adults with brain tumours","volume":"8","author":"Kerrigan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ane.12437-BIB0008|ane12437-cit-0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","article-title":"P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy","volume":"72","author":"Oberndorfer","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1111\/ane.12437-BIB0009|ane12437-cit-0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12437-BIB0010|ane12437-cit-0010","first-page":"47","article-title":"Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents","volume":"7","author":"Ververis","year":"2013","journal-title":"Biologics"},{"key":"10.1111\/ane.12437-BIB0011|ane12437-cit-0011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cell.2007.01.033","article-title":"The mammalian epigenome","volume":"128","author":"Bernstein","year":"2007","journal-title":"Cell"},{"key":"10.1111\/ane.12437-BIB0012|ane12437-cit-0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1111\/ane.12437-BIB0013|ane12437-cit-0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4331\/wjbc.v1.i5.55","article-title":"Deacetylase inhibitors - focus on non-histone targets and effects","volume":"1","author":"Ocker","year":"2010","journal-title":"World J Biol Chem"},{"key":"10.1111\/ane.12437-BIB0014|ane12437-cit-0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.gene.2005.09.010","article-title":"Acetylation and deacetylation of non-histone proteins","volume":"363","author":"Glozak","year":"2005","journal-title":"Gene"},{"key":"10.1111\/ane.12437-BIB0015|ane12437-cit-0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2010.01792.x","article-title":"Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas","volume":"102","author":"Campos","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1111\/ane.12437-BIB0016|ane12437-cit-0016","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbagrm.2010.05.008","article-title":"Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions","volume":"1799","author":"Marks","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/ane.12437-BIB0017|ane12437-cit-0017","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1111\/ane.12437-BIB0018|ane12437-cit-0018","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/ane.12437-BIB0019|ane12437-cit-0019","first-page":"659","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"12","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/ane.12437-BIB0020|ane12437-cit-0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.leu.2404478","article-title":"Chromatin modifications and DNA double-strand breaks: the current state of play","volume":"21","author":"Karagiannis","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/ane.12437-BIB0021|ane12437-cit-0021","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1158\/0008-5472.CAN-09-3848","article-title":"Three-dimensional cell growth confers radioresistance by chromatin density modification","volume":"70","author":"Storch","year":"2010","journal-title":"Cancer Res"},{"key":"10.1111\/ane.12437-BIB0022|ane12437-cit-0022","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","article-title":"Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci","volume":"5","author":"Munshi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/ane.12437-BIB0023|ane12437-cit-0023","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1111\/ane.12437-BIB0024|ane12437-cit-0024","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ane.12437-BIB0025|ane12437-cit-0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","article-title":"Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275","volume":"64","author":"Camphausen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/ane.12437-BIB0026|ane12437-cit-0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ijc.20117","article-title":"Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells","volume":"110","author":"Zhang","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1111\/ane.12437-BIB0027|ane12437-cit-0027","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1111\/ane.12437-BIB0028|ane12437-cit-0028","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ijrobp.2004.03.001","article-title":"Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor","volume":"59","author":"Kim","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/ane.12437-BIB0029|ane12437-cit-0029","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.semcancer.2009.02.005","article-title":"Epigenetic mechanisms in glioblastoma multiforme","volume":"19","author":"Nagarajan","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"10.1111\/ane.12437-BIB0030|ane12437-cit-0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrc1319","article-title":"MGMT: its role in cancer aetiology and cancer therapeutics","volume":"4","author":"Gerson","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/ane.12437-BIB0031|ane12437-cit-0031","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0002-9440(10)64901-2","article-title":"Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma","volume":"160","author":"Kang","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1111\/ane.12437-BIB0032|ane12437-cit-0032","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12437-BIB0033|ane12437-cit-0033","first-page":"793","article-title":"Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia","volume":"59","author":"Esteller","year":"1999","journal-title":"Cancer Res"},{"key":"10.1111\/ane.12437-BIB0034|ane12437-cit-0034","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11060-013-1102-x","article-title":"Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients","volume":"113","author":"Zhang","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1111\/ane.12437-BIB0035|ane12437-cit-0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12437-BIB0036|ane12437-cit-0036","unstructured":"Alberta Provincial CNS Tumour Team Glioblastoma"},{"key":"10.1111\/ane.12437-BIB0037|ane12437-cit-0037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fonc.2012.00098","article-title":"The strategy for enhancing temozolomide against malignant glioma","volume":"2","author":"Nakada","year":"2012","journal-title":"Front Oncol"},{"key":"10.1111\/ane.12437-BIB0038|ane12437-cit-0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","article-title":"Metabolic and endocrine effects of valproic acid chronic treatment","volume":"107","author":"Belcastro","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12437-BIB0039|ane12437-cit-0039","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery-pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1111\/ane.12437-BIB0040|ane12437-cit-0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","article-title":"In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)","volume":"52","author":"Wen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/ane.12437-BIB0041|ane12437-cit-0041","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ceca.2013.08.002","article-title":"Mechanisms for L-channel-mediated increase in [Ca2\u00a0+\u00a0]i and its reduction by anti-bipolar drugs in cultured astrocytes combined with its mRNA expression in freshly isolated cells support the importance of astrocytic L-channels","volume":"54","author":"Yan","year":"2013","journal-title":"Cell Calcium"},{"key":"10.1111\/ane.12437-BIB0042|ane12437-cit-0042","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2012.09.055","article-title":"Valproic acid induces the glutamate transporter excitatory amino acid transporter-3 in human oligodendroglioma cells","volume":"227","author":"Bianchi","year":"2012","journal-title":"Neuroscience"},{"key":"10.1111\/ane.12437-BIB0043|ane12437-cit-0043","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.toxlet.2013.10.035","article-title":"Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells","volume":"224","author":"Kwieci\u0144ska","year":"2014","journal-title":"Toxicol Lett"},{"key":"10.1111\/ane.12437-BIB0044|ane12437-cit-0044","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1111\/ane.12437-BIB0045|ane12437-cit-0045","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/ane.12437-BIB0046|ane12437-cit-0046","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/ane.12437-BIB0047|ane12437-cit-0047","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/ane.12437-BIB0048|ane12437-cit-0048","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate induces replication-independent active DNA demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/ane.12437-BIB0049|ane12437-cit-0049","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgl167","article-title":"Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes","volume":"28","author":"Milutinovic","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1111\/ane.12437-BIB0050|ane12437-cit-0050","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/ane.12437-BIB0051|ane12437-cit-0051","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874467210902010095","article-title":"Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection","volume":"2","author":"Monti","year":"2009","journal-title":"Curr Mol Pharmacol"},{"key":"10.1111\/ane.12437-BIB0052|ane12437-cit-0052","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1471-4159.2002.01081.x","article-title":"Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase","volume":"83","author":"Bacon","year":"2002","journal-title":"J Neurochem"},{"key":"10.1111\/ane.12437-BIB0053|ane12437-cit-0053","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1111\/ane.12437-BIB0054|ane12437-cit-0054","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation","volume":"107","author":"Nifterik","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1111\/ane.12437-BIB0055|ane12437-cit-0055","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ane.12437-BIB0056|ane12437-cit-0056","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00109-010-0707-1","article-title":"Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation","volume":"89","author":"Chen","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"10.1111\/ane.12437-BIB0057|ane12437-cit-0057","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/neuonc\/nop005","article-title":"Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines","volume":"12","author":"Fu","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1111\/ane.12437-BIB0058|ane12437-cit-0058","doi-asserted-by":"crossref","first-page":"987495","DOI":"10.1155\/2012\/987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Ryu","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1111\/ane.12437-BIB0059|ane12437-cit-0059","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-05-2849","article-title":"Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts","volume":"12","author":"Shu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1111\/ane.12437-BIB0060|ane12437-cit-0060","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/ane.12437-BIB0061|ane12437-cit-0061","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1111\/ane.12437-BIB0062|ane12437-cit-0062","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/ane.12437-BIB0063|ane12437-cit-0063","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00381-012-1997-0","article-title":"Survival of children with malignant brain tumors receiving valproate: a retrospective study","volume":"29","author":"Felix","year":"2013","journal-title":"Childs Nerv Syst"},{"key":"10.1111\/ane.12437-BIB0064|ane12437-cit-0064","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","article-title":"Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme","volume":"118","author":"Guthrie","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1111\/ane.12437-BIB0065|ane12437-cit-0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"Br J Neurosurg"},{"key":"10.1111\/ane.12437-BIB0066|ane12437-cit-0066","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","article-title":"Efficacy of anti-epileptic drugs in patients with gliomas and seizures","volume":"256","author":"Breemen","year":"2009","journal-title":"J Neurol"},{"key":"10.1111\/ane.12437-BIB0067|ane12437-cit-0067","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1582-4934.2011.01296.x","article-title":"Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic","volume":"15","author":"Shabason","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1111\/ane.12437-BIB0068|ane12437-cit-0068","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/neuonc\/not095","article-title":"Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1111\/ane.12437-BIB0069|ane12437-cit-0069","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/ane.12437-BIB0070|ane12437-cit-0070","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1212\/WNL.44.8.1418","article-title":"Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration","volume":"44","author":"Gidal","year":"1994","journal-title":"Neurology"},{"key":"10.1111\/ane.12437-BIB0071|ane12437-cit-0071","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/WNL.0b013e31822f0325","article-title":"Valproic acid as the AED of choice for patients with glioblastoma? The jury is out","volume":"77","author":"Wen","year":"2011","journal-title":"Neurology"},{"key":"10.1111\/ane.12437-BIB0072|ane12437-cit-0072","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-014-7552-z","article-title":"Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study","volume":"262","author":"Tinchon","year":"2015","journal-title":"J Neurol"},{"key":"10.1111\/ane.12437-BIB0073|ane12437-cit-0073","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.0013-9580.2004.00104.x","article-title":"The activity of antiepileptic drugs as histone deacetylase inhibitors","volume":"45","author":"Eyal","year":"2004","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12437-BIB0074|ane12437-cit-0074","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.lfs.2005.01.003","article-title":"Carbamazepine is an inhibitor of histone deacetylases","volume":"76","author":"Beutler","year":"2005","journal-title":"Life Sci"},{"key":"10.1111\/ane.12437-BIB0075|ane12437-cit-0075","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e3181bbfeca","article-title":"Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma","volume":"73","author":"Jaeckle","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/ane.12437-BIB0076|ane12437-cit-0076","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/ane.12437-BIB0077|ane12437-cit-0077","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1111\/ane.12437-BIB0078|ane12437-cit-0078","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3171\/2013.1.JNS12397","article-title":"Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors","volume":"118","author":"Saria","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1111\/ane.12437-BIB0079|ane12437-cit-0079","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1200\/JCO.2008.21.6895","article-title":"Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial","volume":"27","author":"Grossman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 9","key":"10.1111\/ane.12437-BIB0080|ane12437-cit-0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/epi.12440","article-title":"Tumoral epileptogenicity: how does it happen?","volume":"54","author":"Pallud","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12437-BIB0081|ane12437-cit-0081","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12437-BIB0082|ane12437-cit-0082","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1535-7511.2010.01374.x","article-title":"Pharmacokinetic interactions with antiepileptic drugs: always the bad actor, or simply misunderstood?","volume":"10","author":"Gidal","year":"2010","journal-title":"Epilepsy Curr"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12437","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12437\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:48:34Z","timestamp":1671540514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12437","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}